Literature DB >> 6801589

Peritonsillar abscess: needle aspiration.

F S Herzon, J H Aldridge.   

Abstract

Needle aspiration and antibiotics (usually penicillin) were used as the sole initial treatment of peritonsillar abscess in 29 patients over a 2 1/2-year period. Positive aspirations occurred in 23 patients, 19 (82%) of whom had complete resolution of their abscesses without further initial therapy. The implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6801589     DOI: 10.1177/019459988108900606

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  Preoperative ultrasonographic verification of peritonsillar abscesses in patients with severe tonsillitis.

Authors:  T Boesen; F Jensen
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

2.  Semiquantitative culture results and pathogenic significance of obligate anaerobes in peritonsillar abscesses.

Authors:  A M Jokipii; L Jokipii; P Sipilä; K Jokinen
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

3.  Peritonsillar abscess: remember to always think twice.

Authors:  Jochen P Windfuhr; Alexandra Zurawski
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-21       Impact factor: 2.503

Review 4.  Indications for tonsillectomy stratified by the level of evidence.

Authors:  Jochen P Windfuhr
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

5.  [Trends and complications in the management of peritonsillar abscess with emphasis on children].

Authors:  J P Windfuhr; S Remmert
Journal:  HNO       Date:  2005-01       Impact factor: 1.284

6.  Epidemiological and Microbiological Aspects of the Peritonsillar Abscess.

Authors:  David Slouka; Jana Hanakova; Tomas Kostlivy; Petr Skopek; Vojtech Kubec; Vaclav Babuska; Ladislav Pecen; Ondřej Topolcan; Radek Kucera
Journal:  Int J Environ Res Public Health       Date:  2020-06-05       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.